PFE

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Friday, August 19, 2022 - 3:00pm
Research, Infectious Diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Safety, NYSE, Vaccine, YouTube, News, PFE, Medicine, EDT, LinkedIn, Science, U.S. Securities and Exchange Commission, Inc., Twitter, CEST, Facebook, Webcast, Clinical trial, Growth, Development, Pharmaceutical industry, Pfizer

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points: 
  • To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

Retrieved on: 
Friday, August 12, 2022 - 11:45am
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Irritability, OPA, Series, NYSE, Senior, Immunoglobulin G, Population, GMC Terrain, Clinical trial, Inc., Streptococcus, PFE, Pain, Fever, Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Vaccine, Safety, Somnolence, Vaccination, Appetite, Infant, NI, Development, IPD, Food, Swelling, Pharmaceutical industry, Pfizer

Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

Key Points: 
  • Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
  • We are grateful to everyone who made this study possible, including the study investigators and in particular the trial participants and their parents/guardians for their contribution to this important research.
  • Overall, the safety profile of the 20vPnC candidate was consistent with Prevnar 13 given in the same schedule.
  • In 2020, Pfizer initiated the Phase 3 clinical trial program for the pediatric indication for 20vPnC.

NextRNA Therapeutics Names Dominique Verhelle as CEO and Expands Leadership Team

Retrieved on: 
Thursday, August 11, 2022 - 7:30pm
Health, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, Immunotherapy, Drug discovery, CEO, NYSE, Medicinal chemistry, Leadership, IFM Therapeutics, LLC, Third Rock Ventures, PFE, Merck, Takeda Pharmaceutical Company, Therapy, Center, IFM, RNA, VP, Doctor of Philosophy, Novartis, MBA, TAK, Protein, Dominique, Disease, NLRP3, Management, Pharmaceutical industry, Pfizer, Celgene

NextRNA Therapeutics , a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive Officer.

Key Points: 
  • NextRNA Therapeutics , a biotechnology company unlocking the potential of non-coding RNAs to develop novel and transformative therapeutics, announces the appointment of Dominique Verhelle, PhD, MBA as the Chief Executive Officer.
  • Dominique is a co-founder of NextRNA who has led the scientific and corporate strategy since its launch over the past year and a half.
  • Prior to NextRNA, Dominique was formerly the Head of Academic Innovation, Center for External Innovation at Takeda Pharmaceutical Company (NYSE: TAK).
  • Dominique was previously a Principal at Third Rock Ventures, where she played an instrumental role in launching Fulcrum Therapeutics (Nasdaq: FULC) and Cedilla Therapeutics.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Professional Holding Corp. (Nasdaq – PFHD), Global Blood Therapeutics, Inc. (Nasdaq – GBT), CyberOptics Corporation (Nasdaq – CYBE), EVO Payments, Inc. (Nasdaq

Retrieved on: 
Thursday, August 11, 2022 - 5:32pm
Brodsky, GLOBE, NYSE, GBT, Pfizer, PFE, Company, GPN, NDSN, Global Payments, Nasdaq, Professional, Security (finance), Nordson Corporation

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.
  • Under the terms of the agreement, Professional will be acquired by Seacoast Banking Corporation of Florida (Seacoast) (Nasdaq -SBCF).
  • Professional shareholders are to receive 0.8909 shares of Seacoast common stock for each share of Professional common stock.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

GLOBAL BLOOD THERAPEUTICS, INC. ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of GBT and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, August 9, 2022 - 9:48pm
P.C, Telephone, NYSE, GLOBE, GBT, Learning, PFE, Pfizer, Acquisition, NASDAQ, Squire, Pharmaceutical industry, Property management

On August 8, 2022, GBT announced that it had entered into an agreement to be acquired by Pfizer in an all-cash deal with an enterprise value of $5.4 billion.

Key Points: 
  • On August 8, 2022, GBT announced that it had entered into an agreement to be acquired by Pfizer in an all-cash deal with an enterprise value of $5.4 billion.
  • Pursuant to the merger agreement, Pfizer will acquire all the outstanding shares of GBT for $68.50 per share in cash.
  • Bragar Eagel & Squire is concerned that GBTs board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT

Retrieved on: 
Monday, August 8, 2022 - 11:24pm
Class Action Lawsuit, Professional Services, Legal, Company, Nasdaq, Sale, LLC, KSF, PFE, NYSE, GBT, Pfizer

and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS: GBT) to Pfizer Inc. (NYSE: PFE).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Global Blood Therapeutics, Inc. (GBT) (NasdaqGS: GBT) to Pfizer Inc. (NYSE: PFE).
  • Under the terms of the proposed transaction, shareholders of GBT will receive $68.50 in cash for each share of GBT that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15

Retrieved on: 
Monday, August 8, 2022 - 9:45pm
U.S. Securities and Exchange Commission, Clinical trial, Facebook, Research, Fever, Arthralgia, Arthritis, Food, Disease, Risk, Erythema, Patent, Biologics license application, Euronext Paris, Marketing, Fatigue, News, Myalgia, Safety, BLA, Science, Nasdaq, Chikungunya, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Joint, Senior, Incidence, Borrelia burgdorferi, European Medicines Agency, COVID-19, Program, Vaccine, VLA, Marketing Authorisation Application, Vaccination, Headache, Fast Track, Time, MAA, FDA, United, NYSE, Carditis, YouTube, Achievement, PFE, Lyme disease, Company, Infection, Twitter, Bacteria, Erythema migrans, Intention, Human, Heart, LinkedIn, EMA, Pharmaceutical industry, Pfizer, Valneva SE

The randomized, placebo-controlled, Phase 3 VALOR study is planned to enroll approximately 6,000 participants 5 years of age and older.

Key Points: 
  • The randomized, placebo-controlled, Phase 3 VALOR study is planned to enroll approximately 6,000 participants 5 years of age and older.
  • As per the terms of the collaboration agreement between Pfizer and Valneva, Pfizer will make a $25 million milestone payment to Valneva upon initiation of the Phase 3 study.
  • VLA15 is the only Lyme disease vaccine candidate currently in clinical development.
  • This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Global Blood Therapeutics, Inc. (Nasdaq – GBT)

Retrieved on: 
Monday, August 8, 2022 - 3:58pm
Brodsky, GLOBE, NYSE, GBT, Suite, Board, Pfizer, PFE, Company, Nasdaq, Pharmaceutical industry

The investigation concerns whether the GBT Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Pfizer is paying too little for the Company.

Key Points: 
  • The investigation concerns whether the GBT Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Pfizer is paying too little for the Company.
  • For example, the deal consideration is below the 52-week high of $73.02 for the Companys shares.
  • You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, visit https://www.brodskysmith.com/cases/global-blood-therapeutics-inc-nasdaq-... , or call toll free 855-576-4847.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis

Retrieved on: 
Saturday, August 6, 2022 - 1:50am
Linda, FDA, Woman, Hospital, Dysmenorrhea, UCSF, Endometriosis, NYSE, Internal medicine, GLOBE, University of California, San Francisco, NEW, Senior, Norethisterone, Roivant Sciences, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pfizer, PFE, Pain, Patient, SPIRIT, Uterine fibroid, Safety, Rusyns, Webcast, Physician, University, Conditional sentence, Chair, Food, Health, Disease, Pharmaceutical industry, Dentistry, Lancet

MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Key Points: 
  • MYFEMBREE offers an effective, once-daily treatment option for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.
  • MYFEMBREE is available immediately to patients with moderate to severe pain associated with endometriosis with a prescription from their healthcare provider.
  • Myovant and Pfizer also are committed to supporting women in the U.S. who are prescribed MYFEMBREE throughout their treatment journeys.
  • Food and Drug Administration for the management of moderate to severe pain associated with endometriosis, with a treatment duration of up to 24 months.

Global Submarine Cable System Markets, 2022-2027: Expanding Offshore Wind Power Capacity & Increasing Investments by Content Delivery and Streaming Partners to Create Opportunities in Pacific - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022 - 4:39pm
Technology, Hardware, Telecommunications, High voltage, SWOT, Investment, Bharti Airtel, COVID-19, Market development, Cable & Wireless Communications, Voltage, SLM, Industry, Component, Cable, PFE, Power cable, Submarine communications cable, Risk, Mbale–Bulambuli–Siti Medium Voltage Power Line, USD, Ansoff Matrix, Application, Geography, CAGR, Communication, Emotion, Competitive analysis, Impact, Growth, Wireless, Satellite navigation device, Retail, Risk management, Electrical cable, Maintenance

The Global Submarine Cable System Market is estimated to be USD 14.9 Bn in 2022 and is projected to reach USD 25.68 Bn by 2027, growing at a CAGR of 11.5%.

Key Points: 
  • The Global Submarine Cable System Market is estimated to be USD 14.9 Bn in 2022 and is projected to reach USD 25.68 Bn by 2027, growing at a CAGR of 11.5%.
  • Market dynamics are forces that impact the prices and behaviors of the Global Submarine Cable System Market stakeholders.
  • These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service.
  • The report presents a detailed Ansoff matrix analysis for the Global Submarine Cable System Market.